The largest community of pharma leaders

Tychan to Start COVID-19 Phase 3 Clinical Trial For Novel Monoclonal Antibody TY027

SINGAPORE–(BUSINESS WIRE)–In June 2020, Tychan began its Phase 1 clinical safety trials in humans to evaluate TY027, a monoclonal antibody (mAb) that specifically targets SARS-CoV-2, the virus that causes COVID-19. In October 2020, approval from Health Sciences Authority of Singapore (HSA) was obtained for the Phase 3 clinical trial to begin as part of the progression of the antibody development. The trial will start in Singapore at partner hospitals Singapore General Hospital and National Un

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles